These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 27528374)

  • 21. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Bae JH; Kim S; Park EG; Kim SG; Hahn S; Kim NH
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):80-92. PubMed ID: 30912341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks.
    Chai S; Yu S; Yang Z; Wu S; Gao L; Wang H; Zhang Y; Zhan S; Ji L; Sun F
    BMJ Open Diabetes Res Care; 2019; 7(1):e000728. PubMed ID: 31641525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Pieters IC; Cahen DL; Diamant M; van Raalte DH
    BMJ Open; 2015 Nov; 5(11):e009579. PubMed ID: 26586327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence.
    Seksaria S; Dutta BJ; Kaur M; Gupta GD; Bodakhe SH; Singh A
    Curr Diabetes Rev; 2024; 20(6):e090823219597. PubMed ID: 37559236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
    Drab SR
    Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis.
    Cheng D; Fei Y; Liu Y; Li J; Chen Y; Wang X; Wang N
    PLoS One; 2014; 9(10):e111543. PubMed ID: 25360775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ
    Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD.
    Allegretti AS; Zhang W; Zhou W; Thurber TK; Rigby SP; Bowman-Stroud C; Trescoli C; Serusclat P; Freeman MW; Halvorsen YC
    Am J Kidney Dis; 2019 Sep; 74(3):328-337. PubMed ID: 31101403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis.
    Wang W; Gao Y; Chen D; Wang C; Feng X; Ran X
    Diabetes Res Clin Pract; 2017 Jul; 129():213-223. PubMed ID: 28552612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.
    Gargiulo P; Savarese G; D'Amore C; De Martino F; Lund LH; Marsico F; Dellegrottaglie S; Marciano C; Trimarco B; Perrone-Filardi P
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1081-1088. PubMed ID: 29113708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence-based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease.
    Tuttle KR; McGill JB
    Diabetes Obes Metab; 2020 Jul; 22(7):1014-1023. PubMed ID: 32009296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease.
    Kamiya H
    Hemodial Int; 2017 Jan; 21(1):72-83. PubMed ID: 27436163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials.
    Alfayez OM; Almutairi AR; Aldosari A; Al Yami MS
    Can J Diabetes; 2019 Oct; 43(7):538-545.e2. PubMed ID: 31175007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.
    Zarowitz BJ; Conner C
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):55S-67S. PubMed ID: 19947817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of patients with type 2 diabetes mellitus: cardiovascular safety of incretin-based therapy supported by the ELIXA and TECOS trials].
    Avogaro A
    G Ital Cardiol (Rome); 2016 Apr; 17(4):248-52. PubMed ID: 27093207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis.
    Wang C; Zhou Y; Kong Z; Wang X; Lv W; Geng Z; Wang Y
    Diabetes Obes Metab; 2019 Apr; 21(4):1018-1026. PubMed ID: 30565382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.